Leerink Partnrs Has Positive Outlook of Sanofi Q1 Earnings

Sanofi (NASDAQ:SNY) – Stock analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Sanofi in a research report issued on Thursday, January 30th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $0.85 per share for the quarter, up from their prior estimate of $0.75. The consensus estimate for Sanofi’s current full-year earnings is $4.34 per share. Leerink Partnrs also issued estimates for Sanofi’s Q2 2025 earnings at $0.92 EPS, Q4 2025 earnings at $0.92 EPS and FY2029 earnings at $5.94 EPS.

Several other equities research analysts also recently weighed in on the stock. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $53.50 on Monday. The stock has a market cap of $135.77 billion, a P/E ratio of 21.49, a P/E/G ratio of 1.26 and a beta of 0.57. The stock has a 50 day moving average of $49.44 and a two-hundred day moving average of $52.34. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently made changes to their positions in SNY. Jennison Associates LLC lifted its stake in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. DAVENPORT & Co LLC raised its holdings in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.